MX2021010595A - Composicion farmaceutica, preparacion y usos de la misma. - Google Patents

Composicion farmaceutica, preparacion y usos de la misma.

Info

Publication number
MX2021010595A
MX2021010595A MX2021010595A MX2021010595A MX2021010595A MX 2021010595 A MX2021010595 A MX 2021010595A MX 2021010595 A MX2021010595 A MX 2021010595A MX 2021010595 A MX2021010595 A MX 2021010595A MX 2021010595 A MX2021010595 A MX 2021010595A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compound
carrier
biocompatible nanoparticle
subject
need
Prior art date
Application number
MX2021010595A
Other languages
English (en)
Inventor
Laurent Levy
Agnès Pottier
Matthieu Germain
Marie- Edith Meyre
Original Assignee
Curadigm Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curadigm Sas filed Critical Curadigm Sas
Publication of MX2021010595A publication Critical patent/MX2021010595A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Abstract

La presente invención se refiere a una composición farmacéutica que comprende la combinación de (i) al menos una nanopartícula biocompatible y de (ii) al menos un vehículo que comprende al menos un compuesto farmacéutico, para administración a un sujeto que precisa dicho compuesto farmacéutico, en donde la combinación de la al menos una nanopartícula biocompatible y el al menos un vehículo que comprende el(los) compuesto(s) farmacéutico(s) potencia el(los) compuesto(s) de eficacia de interés. La dimensión más larga de la nanopartícula biocompatible está normalmente entre aproximadamente 4 y aproximadamente 500 nm y su valor absoluto de carga superficial es de al menos 10 mV (|10 mV|). El vehículo además está desprovisto de cualquier agente estéricamente estabilizador de superficie. La invención también se refiere a dicha composición para su uso en la administración del(de los) compuesto(s) farmacéutico(s) en un sujeto que lo precisa, en donde la al menos una nanopartícula biocompatible y el al menos un vehículo que comprende el al menos un compuesto farmacéutico se administran por separado en un sujeto que necesita dicho compuesto farmacéutico, normalmente entre más de 5 minutos y aproximadamente 72 horas uno con respecto a otro.
MX2021010595A 2014-11-25 2017-05-24 Composicion farmaceutica, preparacion y usos de la misma. MX2021010595A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14306875 2014-11-25

Publications (1)

Publication Number Publication Date
MX2021010595A true MX2021010595A (es) 2021-09-23

Family

ID=52013982

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017006812A MX2017006812A (es) 2014-11-25 2015-11-24 Composición farmacéutica, preparación y usos de la misma.
MX2021010595A MX2021010595A (es) 2014-11-25 2017-05-24 Composicion farmaceutica, preparacion y usos de la misma.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017006812A MX2017006812A (es) 2014-11-25 2015-11-24 Composición farmacéutica, preparación y usos de la misma.

Country Status (18)

Country Link
US (1) US10765632B2 (es)
EP (1) EP3236934A1 (es)
JP (1) JP6789960B2 (es)
KR (1) KR20170093860A (es)
CN (1) CN107106703A (es)
AR (1) AR102782A1 (es)
AU (1) AU2015352685B2 (es)
BR (1) BR112017010953B1 (es)
CA (1) CA2968919C (es)
EA (1) EA201791147A1 (es)
HK (1) HK1245085A1 (es)
IL (2) IL252462B (es)
MX (2) MX2017006812A (es)
NZ (1) NZ769187A (es)
SG (1) SG11201704219UA (es)
TW (1) TW201628656A (es)
UA (1) UA123665C2 (es)
WO (1) WO2016083333A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015016456A (es) 2013-05-30 2016-03-03 Nanobiotix Composicion farmaceutica, preparacion y sus usos.
PT3229843T (pt) 2014-11-25 2020-03-06 Curadigm Sas Composição farmacêutica, a sua preparação e as suas utilizações
JP6835733B2 (ja) 2014-11-25 2021-02-24 キュラディグム・エスアエスＣｕｒａｄｉｇｍ Ｓａｓ 医薬組成物、その調製法及び使用
EP3229776B1 (en) 2014-11-25 2023-06-28 Curadigm Sas Pharmaceutical composition combining at least two distinct nanoparticles and a pharmaceutical compound, preparation and uses thereof
TW201705977A (zh) 2015-05-28 2017-02-16 奈諾生技公司 作為治療疫苗之奈米顆粒

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4280918A (en) 1980-03-10 1981-07-28 International Business Machines Corporation Magnetic particle dispersions
GB9509321D0 (en) 1995-05-09 1995-06-28 Zylepsis Ltd Methods of and substances for inhibiting oxidative enzymes
JPH10120597A (ja) 1996-10-22 1998-05-12 Eiken Chem Co Ltd リンパ節高集積性コロイド粒子
US20050090732A1 (en) 2003-10-28 2005-04-28 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles
CN100563718C (zh) * 2003-12-22 2009-12-02 伯拉考开发股份有限公司 用于反差成像的充气微囊组件
JP2007523090A (ja) * 2004-02-10 2007-08-16 バーンズ−ジューイッシュ ホスピタル デコイ系を用いたターゲティングされた微粒子剤の有効性および安全性の改善方法
US20060264804A1 (en) * 2005-04-07 2006-11-23 Yoram Karmon Device and kit for delivery of encapsulated substances and methods of use thereof
WO2006127962A2 (en) * 2005-05-25 2006-11-30 Becton, Dickinson And Comapny Particulate formulations for intradermal delivery of biologically active agents
DE102005039579B4 (de) 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
US20090130050A1 (en) * 2006-03-24 2009-05-21 Toto Ltd. Titanium Oxide Composite Particles, Dispersion Liquid Thereof, and Process for Producing Them
US20100233219A1 (en) 2006-03-30 2010-09-16 Fujifilm Corporation Inorganic nanoparticle compromising an active substance immobilized on the surface and a polymer
JP2009536162A (ja) 2006-05-04 2009-10-08 ユニバーシティー オブ サウス オーストラリア ナノ粒子被覆カプセルからの薬物放出
US20090092661A1 (en) * 2007-08-21 2009-04-09 Anthony Huang Liposome compositions for in vivo administration of boronic acid compounds
FR2922106B1 (fr) 2007-10-16 2011-07-01 Univ Claude Bernard Lyon Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants.
EP2231765A2 (en) 2007-12-21 2010-09-29 University Of Guelph Polysaccharide nanoparticles
WO2009105774A2 (en) 2008-02-21 2009-08-27 Sequoia Pharmaceuticals, Inc. Amino acid inhibitors of cytochrome p450
WO2009142754A1 (en) 2008-05-22 2009-11-26 Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dendritic conjugates and methods of use
EP2130553A1 (en) 2008-06-05 2009-12-09 Nanobiotix Inorganic nanoparticles of high density to destroy cells in-vivo
US20130023714A1 (en) 2008-10-26 2013-01-24 Board Of Regents, The University Of Texas Systems Medical and Imaging Nanoclusters
GB0921596D0 (en) 2009-12-09 2010-01-27 Isis Innovation Particles for the treatment of cancer in combination with radiotherapy
CN102781472B (zh) 2010-02-17 2014-07-02 国立大学法人神户大学 放射线治疗剂
HUE027749T2 (en) 2010-03-26 2016-10-28 Abraxis Bioscience Llc Methods of treating hepatocellular carcinoma
GB201009455D0 (en) 2010-06-04 2010-07-21 King S College London Nanoparticles and their uses in molecular imaging
WO2012051220A1 (en) 2010-10-11 2012-04-19 Wichita State University Composite magnetic nanoparticle drug delivery system
US20140227343A1 (en) 2011-01-31 2014-08-14 Centre National De La Recherche Scientifique Method of monitoring the release from liposomes of a product of interest using superparamagnetic nanoparticles
DK2670394T3 (en) 2011-01-31 2019-01-14 Nanobiotix NANOPARTICLE DELIVERY SYSTEMS, PREPARATION AND APPLICATIONS THEREOF
US10251841B2 (en) 2011-10-17 2019-04-09 Trustees Of Boston University Polymeric depots for localization of agent to biological sites
US20150209397A1 (en) 2012-09-07 2015-07-30 Carnegie Mellon University Methods and materials for reducing reticuloendothelial system clearance of particles from a subject
ITRM20120480A1 (it) 2012-10-09 2014-04-10 Uni Degli Studi Camerino Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione.
US20140186447A1 (en) 2012-12-28 2014-07-03 Abraxis Bioscience, Llc Nanoparticle compositions of albumin and paclitaxel
MX2015016456A (es) * 2013-05-30 2016-03-03 Nanobiotix Composicion farmaceutica, preparacion y sus usos.
EP2886128A1 (en) 2013-12-20 2015-06-24 Nanobiotix Pharmaceutical composition comprising nanoparticles, preparation and uses thereof
MX2017006813A (es) 2014-11-25 2018-01-30 Nanobiotix Composicion farmaceutica, preparacion y usos de la misma.
EP3229776B1 (en) * 2014-11-25 2023-06-28 Curadigm Sas Pharmaceutical composition combining at least two distinct nanoparticles and a pharmaceutical compound, preparation and uses thereof
JP6835733B2 (ja) 2014-11-25 2021-02-24 キュラディグム・エスアエスＣｕｒａｄｉｇｍ Ｓａｓ 医薬組成物、その調製法及び使用
PT3229843T (pt) 2014-11-25 2020-03-06 Curadigm Sas Composição farmacêutica, a sua preparação e as suas utilizações

Also Published As

Publication number Publication date
HK1245085A1 (zh) 2018-08-24
US20170258721A1 (en) 2017-09-14
SG11201704219UA (en) 2017-06-29
NZ769187A (en) 2023-07-28
CA2968919C (en) 2023-07-18
EP3236934A1 (en) 2017-11-01
CN107106703A (zh) 2017-08-29
BR112017010953B1 (pt) 2024-01-16
EA201791147A1 (ru) 2017-11-30
AU2015352685B2 (en) 2020-09-17
MX2017006812A (es) 2018-02-12
AU2015352685A1 (en) 2017-07-13
CA2968919A1 (en) 2016-06-02
KR20170093860A (ko) 2017-08-16
IL290114A (en) 2022-03-01
BR112017010953A2 (pt) 2018-02-14
WO2016083333A1 (en) 2016-06-02
US10765632B2 (en) 2020-09-08
TW201628656A (zh) 2016-08-16
JP6789960B2 (ja) 2020-11-25
NZ732995A (en) 2021-01-29
IL252462A0 (en) 2017-07-31
JP2017538783A (ja) 2017-12-28
IL252462B (en) 2022-03-01
UA123665C2 (uk) 2021-05-12
AR102782A1 (es) 2017-03-22

Similar Documents

Publication Publication Date Title
NZ714273A (en) Pharmaceutical composition comprising the combination of a biocompatible nanoparticle and a compound of interest, preparation and uses thereof
MX2021010595A (es) Composicion farmaceutica, preparacion y usos de la misma.
MX2017006813A (es) Composicion farmaceutica, preparacion y usos de la misma.
MX2023000745A (es) Composiciones para usarse en el suministro de agentes biomacromoleculares.
WO2017042607A3 (en) Compositions comprising meloxicam-cyclodextrin inclusion complexes and methods of treating acute pain
MY196319A (en) Polycyclic TLR7/8 Antagonists and use Thereof in the Treatment of Immune Disorders
MX2019015578A (es) Metodos para tratar la enfermedad de huntington.
MX2019007187A (es) Composiciones para el cuidado bucal.
WO2014113429A3 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
MX355330B (es) Formas cristalinas de compuestos terapeuticos y sus usos.
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
EP2576578A4 (en) POLYMORPHES OF 2'-O-FUCOSYLLACTOSE AND MANUFACTURE THEREOF
WO2015023691A3 (en) 4-methylumbelliferone treatment for immune modulation
WO2015104292A3 (en) Compounds for use in treating or preventing cancerous diseases
MY173573A (en) Pyridin-4-yl derivatives
SG10201810404XA (en) Combination comprising a glucocorticoid and edo-s101
MY179605A (en) Use of benzimidazole-proline derivatives
PH12016501519B1 (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MX2017016231A (es) Compuestos de aminobencisoxazol como agonistas de receptores a7-nicotínicos de acetilcolina.
SG10201907289VA (en) Monomethylfumarate prodrug compositions
AR102778A1 (es) Composición farmacéutica, su preparación y sus usos
WO2016040814A3 (en) Disulfide polymers and methods of use
NZ757526A (en) Naphthoquinones, their derivatives and uses thereof in methods for the treatment of mitochondrial dysfunction
MX2015011588A (es) Tratamiento de combinacion.
IN2013MU01177A (es)